Relationship between glycaemic control and weight loss with once-weekly efpeglenatide in uncontrolled type 2 diabetes: a subanalysis of EXCEED 203

Publication Authors:

Michael Trautmann, Rosenstock J, Morales C, Wendisch U, Dailey G, Hompesch M, Choi IY, Kang J, Stewart J, Ogbaa I, Sorli C, Yoon K

Poster presented at 55th Annual Meeting of the European Association for the Study of Diabetes (EASD), Barcelona, Spain. 2019 Sept.

About

About this poster:

Efpeglenatide is a long-acting glucagon-like peptide-1 receptor agonist (GLP-1 RA), administered by once-weekly (QW) subcutaneous injection, currently being developed to improve glycaemic control in patients with type 2 diabetes (T2D). EXCEED 203, a 12-week study of efpeglenatide (0.3, 1, 2, 3, or 4 mg QW) compared with placebo (PBO) and referenced to open-label liraglutide 1.8 mg in uncontrolled T2D (naïve/metformin monotherapy), found significantly improved HbA1c for all doses of efpeglenatide ≥1 mg, and reductions in body weight for efpeglenatide 3 and 4 mg.

VIEW
Relationship between glycaemic control and weight loss with once-weekly efpeglenatide in uncontrolled type 2 diabetes: a subanalysis of EXCEED 203 thumbnail